Houston KA, et al. - This trial gauged the existence of similar decreases in the prevalence of prostate-specific antigen (PSA) screening and prostate cancer incidence rates, following the US Preventive Service Task Force (USPSTF) recommendations against routine PSA, across socioeconomic groups and US census regions. The early-stage disease in men 50 years and older, reported a decrease in the prostate cancer incidence. On the other hand, the rates for distant-stage disease illustrated a minor increase in men 50-74 years following USPSTF recommendations against routine PSA screening. In order to affirm the yielded results and to monitor the upshot of late-stage disease increase on prostate cancer mortality rates, additional analyses were requisited.

Methods

• The incidence rates and PSA screening prevalence were contemplated by age, race/ethnicity, disease stage, US region, and area-level socioeconomic status.
• An inspection was pursued of the annual percent changes for variations in the rates over time.
• This was followed by an estimation of the predicted marginal probability and 95% confidence intervals (CI) to determine the changes in PSA screening.

Results

• Decreased incidence rates were reported for men aged ≥50 years, in all race/ethnic, regional, and SES groups.
• The overall incidence rates for localized cancers decreased notably by 7.5% (95% CI; -10.5, -4.4) per year in age 50-74 years and by 11.1% (95% CI; -14.1, -8.1) per year in aged ≥75 years, from 2007-2013.
• The incidence for distant-stage cancer, on the other hand, displayed a marked rise by 1.4% (95% CI; 0.3, 2.5) per year from 2008-2013 in age 50-74 years.
• However, it stabilized from 2011-2013 in age ≥75 years (5.1% per year, 95% CI; -3.4, 14.4).
• Increased distant-stage disease rates were unveiled with increasing poverty-level in age 50-74, but not in age ≥75 years.